KISUNLA (donanemab), a new Alzheimer's treatment, has been approved in Australia for early-stage patients with a specific genetic profile and confirmed amyloid plaque build-up. It’s the first treatment in 25 years to target the disease's cause by clearing brain plaques. Administered monthly, Kisunla aims to preserve independence longer. With 450,000 Australians in early stages potentially eligible, the drug’s PBS listing will be reviewed in July. Experts call it a breakthrough and urge support for early detection and access.
25 June 2025
Posted by
editor
ALZHEIMERS DRUG APPROVEDS FOR DISPENSING
-
font size
decrease font size
increase font size
editor
Publisher
Michael Walls
michael@accessnews.com.au
0407 783 413
Login to post comments